RT Journal Article
SR Electronic
T1 Decoy Oligodeoxynucleotide Characterization of Transcription Factors Controlling Endothelin-B Receptor Expression in Vascular Smooth Muscle Cells
JF Molecular Pharmacology
JO Mol Pharmacol
FD American Society for Pharmacology and Experimental Therapeutics
SP 1333
OP 1340
DO 10.1124/mol.58.6.1333
VO 58
IS 6
A1 Andreas H. Wagner
A1 Robert Krzesz
A1 Dingcheng Gao
A1 Christian Schroeder
A1 Marco Cattaruzza
A1 Markus Hecker
YR 2000
UL http://molpharm.aspetjournals.org/content/58/6/1333.abstract
AB Endothelin-1 is not only a powerful vasoconstrictor but also a potent mitogen for vascular smooth muscle cells (SMC), acting through both the endothelin-A and endothelin-B receptor (ETB-R). Although vascular SMC are known to express the ETB-R, its transcriptional regulation has not been studied thus far. Here we demonstrate that the potent inhibitor of nuclear factor κB activation, pyrrolidine dithiocarbamate (PDTC; 30–100 μM), induces de novo ETB-R expression in rat aortic and mesenteric cultured SMC. Electrophoretic mobility shift analyses revealed that besides inhibition of nuclear factor κB, PDTC enhances activator protein-1 (AP-1), CCAAT/enhancer-binding protein (C/EBP), and GATA-2 activity in these cells. Preincubation of PDTC-stimulated cells with appropriate decoy oligodeoxynucleotides confirmed the involvement of these three transcription factors, namely that of AP-1, in ETB-R expression. The stimulatory effect of PDTC on ETB-R expression was also confirmed functionally by monitoring an enhanced ET-1-induced apoptosis in PDTC-treated cells that was sensitive to the ETB-R antagonist, BQ788. Taken together, these findings demonstrate that C/EBP, GATA-2, and in particular AP-1 can control ETB-R expression in vascular SMC. They further support the notion that ETB-R expression in these cells may play an important role in cardiovascular complications, such as restenosis following angioplasty that in the early phase is characterized by prominent SMC apoptosis.